Core Viewpoint - The company Enhua Pharmaceutical (002262.SZ) has made progress in the registration application for its raw material drug NH600001, which was accepted on July 29, 2025 [2] Group 1: Company Updates - The NDA (New Drug Application) for NH600001 has been submitted and is currently under review [2] - All subjects have completed the clinical trial for NH600001 emulsion injection, and data analysis is ongoing [2] - The company plans to submit the market registration application after completing the clinical summary report [2]

Core Points - Enhua Pharmaceutical (002262) announced on August 4 that the registration application for the raw material drug NH600001 was accepted on July 29, 2025 [1] - The clinical trial for NH600001 emulsion injection has completed participant recruitment, and data analysis is currently underway [1] - A summary report of the clinical trial will be submitted for the registration application upon completion [1]